15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index; 86 of the 155 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care section summarizes clinical practice recommendations for managing diabetes in pregnancy, covering preconception care, glycemic targets, gestational diabetes, preexisting type 1/type 2 diabetes, preeclampsia prevention, and postpartum care. It is a guideline synthesis rather than a primary study, with recommendations graded by available evidence.
Key findings
- Preconception care should target A1C <6.5% (<48 mmol/mol) to reduce congenital anomalies, preeclampsia, macrosomia, and preterm birth; preconception care in preexisting diabetes was associated with lower A1C and reduced birth defects, preterm delivery, perinatal mortality, small-for-gestational-age births, and NICU admissions.
- Pregnancy glucose goals are fasting plasma glucose <95 mg/dL (<5.3 mmol/L) and either 1-h postprandial <140 mg/dL (<7.8 mmol/L) or 2-h postprandial <120 mg/dL (<6.7 mmol/L); A1C goal is <6% (<42 mmol/mol) if achievable without significant hypoglycemia, relaxed to <7% (<53 mmol/mol) if needed. CGM is recommended in type 1 diabetes pregnancy, with target sensor range 63–140 mg/dL (3.5–7.8 mmol/L) and TIR goal >70%.
- For GDM, lifestyle behavior change is essential and may suffice; insulin is preferred when medication is needed. Metformin and glyburide should not be first-line because both cross the placenta; 70–85% of people with GDM by Carpenter-Coustan criteria can manage with lifestyle alone, while glyburide and metformin failed adequate glycemic outcomes in 23% and 25–28% of participants, respectively.
- Postpartum, GDM history should be screened at 4–12 weeks with a 75-g OGTT; lifetime maternal diabetes risk is 50–60%, with a 10-fold increased risk of type 2 diabetes versus no GDM. Lifestyle intervention and metformin reduced progression to diabetes by 35% and 40%, respectively, over 10 years; insulin requirements are often roughly half prepregnancy levels initially postpartum, and one study found they were 34% lower.
Methods
- This is an ADA “Standards of Care in Diabetes—2024” clinical practice guideline section, produced by the ADA Professional Practice Committee, which updates recommendations annually or more frequently as warranted.
- It synthesizes evidence from observational studies, RCTs, systematic reviews, and meta-analyses; no new primary data collection or trial is reported.
- Recommendations are organized across preconception counseling, glycemic goals, glucose monitoring, GDM management, preexisting type 1 and type 2 diabetes, preeclampsia/aspirin, pregnancy drug considerations, and postpartum care.
Limitations
- The paper states there are no adequately powered randomized trials comparing different fasting and postmeal glycemic goals for preexisting diabetes in pregnancy; data are insufficient to support CGM in all people with type 2 diabetes or GDM; long-term safety data for offspring exposed to glyburide are not available; and there are no intervention trials in offspring of mothers with GDM.
- It also notes that the most appropriate hypoglycemia threshold in pregnancy has not been validated, and that observational preconception A1C data are confounded by other self-care behaviors.
- Evident from the text: several recommendations rely on expert opinion or limited evidence, including some graded E, and some management decisions are individualized because of insufficient data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
69 Valid · 3 Not valid · 30 Not checked · 1 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the presence of microvascular complications is associated with higher risk of disease progression and adverse pregnancy outcomes (22).”
What the sources say
- Supportedcites [22] Relph, 2021, Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis, PLoS Med source
The Discussion’s Main findings section reports greater risks of adverse maternal and offspring outcomes in pregnant women with preexisting diabetes and microvascular disease. The Results table on risk factors for progression also associates existing retinopathy and nephropathy with worsening or new-onset retinopathy during pregnancy. The claim is supported in this pregnancy-and-diabetes context. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“There are insufficient data to support the use of CGM in all people with type 2 diabetes or GDM (53,54).”
What the sources say
- Not checked — no full text of the sourcecites [53] García-Moreno, 2022, Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials, Diabet Med source
- Partly supportedcites [54] Wyckoff, 2021, Time in range in pregnancy: is there a role?, Diabetes Spectr sourceExperimental — accuracy not yet measured
The section on trials in type 2 diabetes or GDM says that CGM outcomes data are far less robust, with no RCTs specifically studying type 2 diabetes in pregnancy and limited data for GDM. That supports caution about universal CGM use during pregnancy, but the source does not address all people with type 2 diabetes outside pregnancy, as the citing sentence could imply. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cost of CGM in pregnancies complicated by type 1 diabetes is offset by improved maternal and neonatal outcomes (52).”
What the sources say
- Supportedcites [52] Ahmed, 2021, The cost implications of continuous glucose monitoring in pregnant women with type 1 diabetes in 3 Canadian provinces: a posthoc cost analysis of the CONCEPTT trial, CMAJ Open source
The Interpretation conclusion says that, for pregnant patients with type 1 diabetes, governments could pay up to $1372 for CGM devices and sensors without increasing overall costs compared with SMBG, while improving maternal and neonatal outcomes. The Abstract Interpretation attributes the cost balance in part to lower neonatal intensive care costs. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In studies of individuals without preexisting diabetes, increasing A1C levels within the normal range are associated with adverse outcomes (38).”
What the sources say
- Partly supportedcites [38] Ho, 2017, Associations of mid-pregnancy HbA1c with gestational diabetes and risk of adverse pregnancy outcomes in high-risk Taiwanese women, PLoS One sourceExperimental — accuracy not yet measured
The Discussion and Results (Table 1; page numbers unavailable) associate higher mid-pregnancy HbA1c with several adverse pregnancy outcomes among women without overt diabetes, including at levels below 6.0%. The study is limited to high-risk pregnant Taiwanese women with positive glucose-challenge screens, so it does not establish the claim for individuals generally; the Discussion also describes the overall risk pattern as J-shaped, not uniformly increasing. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Observational studies in preexisting diabetes and pregnancy show the lowest rates of adverse fetal outcomes in association with A1C <6-6.5% (<42-48 mmol/mol) early in gestation (4-6,40).”
What the sources say
- Partly supportedcites [4] Jensen, 2009, Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
Table 1 and the Results show the lowest observed rate of serious adverse outcomes in the lowest peri-conceptional A1C category, <6.9%, among women with type 1 diabetes. The paper does not distinguish outcomes below 6–6.5% or establish that narrower range as the lowest-risk threshold; its conclusion supports a preconceptional A1C target of <7%. (LLM, conf=0.88)
- Partly supportedcites [5] Suhonen, 2000, Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus, Diabetologia sourceExperimental — accuracy not yet measured
The Results (p. 3) show the lowest observed major-malformation rate in the HbA1c <5.6% group, measured before 14 weeks of gestation. This supports an association between lower early-pregnancy HbA1c and fewer malformations, but the paper does not establish a 6–6.5% cutoff or assess adverse fetal outcomes broadly; its study population was women with Type I diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [6] Nielsen, 2006, HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes, Diabetes Care source
- Not checked — no full text of the sourcecites [40] Maresh, 2015, Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes, Diabetes Care source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
61 more claims · 35 with their cited sources checked
Create a free account to see all 103 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 1
Citations
Cites
Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect
Victora, C. G., Bahl, R., Barros, A. J. D., França, G. V. A., Horton, S., Krasevec, J., Murch, S., Sankar, M. J., Walker, N., & Rollins, N. C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01024-7 · Cited by 8,040
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Weight Gain During Pregnancy: Reexamining the Guidelines
Rasmussen, K. M., & Yaktine, A. L. (2009) · Cited by 4,473
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik, D. L., Wright, D., Poon, L. C., O’Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704559 · Cited by 2,287
Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., Hall, D. R., Warren, C. E., Adoyi, G., & Ishaku, S. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10803 · Cited by 2,089
Metzger, B. E., Buchanan, T. A., Coustan, D. R., de Leiva, A., Dunger, D. B., Hadden, D. R., Hod, M., Kitzmiller, J. L., Kjos, S. L., Oats, J. N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-s225 · Cited by 1,908
ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Research works printed but not linked: 2
- 2006, Dietary Reference Intakes: The Essential Guide to Nutrient Requirements
- Henderson JT , VescoKK, SengerCA, . Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality (Evidence Synthesis, no. 205). Rockville, MD, Agency for Healthcare Research and Quality. Accessed 17 October 2023. Available from https://www.ncbi.nlm.nih.gov/books/NBK574449/
Cited by
Magnesium Matters: A Comprehensive Review of Its Vital Role in Health and Diseases
Fatima, G., Džupina, A., Al-Hmadi, H. B., Magomedova, A. G., Siddiqui, Z., Mehdi, A., & Hadi, N. R. (2024) · Cureus · doi:10.7759/cureus.71392 · Cited by 155
“Mg requirements are higher for adolescents, individuals with high physical activity levels, and those with certain medical conditions such as diabetes and hypertension [11].”
Wyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf288 · Cited by 59
Crawford, A. L., & Laiteerapong, N. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202406180 · Cited by 54
Metformin beyond type 2 diabetes: Emerging and potential new indications
Petrie, J. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15756 · Cited by 53
Reddy, M., & Oliver, N. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15504 · Cited by 47
“33 The ADA standards also highlight that those offered rtCGM have to be capable of using the devices safely (either by themselves or with a caregiver) and that the choice of device should be made based on the individual's circumstances, preferences and needs.”
BackgroundBeunen, K., Gillard, P., Wilder, N. V., Ballaux, D., Vanhaverbeke, G., Taes, Y., Aers, X.-P., Nobels, F. R. E., Huffel, L. V., Marlier, J., et al. (2024) · Diabetes Care · doi:10.2337/dc24-1320 · Cited by 38
Silverii, G. A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15749 · Cited by 33
Zhang, Z., Wang, Y., Lu, J., & Zhou, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16033 · Cited by 37
“36 Moreover, the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study revealed continuous associations of maternal glucose levels, below the OGTT thresholds for gestational diabetes mellitus (GDM), with heightened risk of neonatal outcomes including large-for-gestational-age.”
Gestational Diabetes: An Update 60 Years After O’Sullivan and Mahan
McIntyre, H. D., Kampmann, U., Dalsgaard Clausen, T., Laurie, J., & Ma, R. C. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae709 · Cited by 32
Benhalima, K., Geerts, I., Calewaert, P., Rijsselberghe, M. V., Lee, D., Bochanen, N., Verstraete, S., Buyse, L., Lewi, L., Caron, R., et al. (2024) · Acta Clinica Belgica · doi:10.1080/17843286.2024.2384258 · Cited by 38
“GDM is generally defined as diabetes diagnosed in pregnancy provided that overt diabetes at the beginning of pregnancy has been excluded [2].”
Point-of-care HbA1c in clinical practice: caveats and considerations for optimal use
Sacks, D. B., Kirkman, M. S., & Little, R. R. (2024) · Diabetes Care · doi:10.2337/dci23-0040 · Cited by 29
Rosenfeld, R. M., Grega, M. L., Karlsen, M. C., Dabrh, A. M. A., Aurora, R. N., Bonnet, J. P., Donnell, L., Fitzpatrick, S. L., Frates, E. P., Joy, E. A., et al. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251325488 · Cited by 54
Diagnosis and Treatment of Hyperglycemia in Pregnancy
Mohan, S., & Egan, A. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.05.011 · Cited by 41
Popova, P., Isakov, A. O., Rusanova, A. N., Sitkin, S. I., Anopova, A. D., Vasukova, E. A., Tkachuk, A., Nemikina, I. S., Stepanova, E. A., Eriskovskaya, A. I., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00650-9 · Cited by 27
Diabetes Management in Detention Facilities: A Statement of the American Diabetes Association
Lorber, D. L., ElSayed, N. A., Bannuru, R. R., Shah, V. N., Puisis, M., Crandall, J. P., Fech-Baughman, S., Wakeen, B., Dantone, J. J., Buskey, R. H., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0015 · Cited by 25
Self-citationThe use of technology in type 2 diabetes and prediabetes: a narrative review
Liarakos, A. L., Lim, J. Z. M., Leelarathna, L., & Wilmot, E. G. (2024) · Diabetologia · doi:10.1007/s00125-024-06203-7 · Cited by 27
“Although the International Consensus on Time in Range defines CGM target ranges for people with diabetes, there are currently no internationally agreed goals for pregnant women with type 2 diabetes [88, 90].”
BackgroundWyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf116 · Cited by 30
Continuous Glucose Monitoring for Management of Type 2 Diabetes and Perinatal Outcomes
Padgett, C. E., Ye, Y., Champion, M. L., Fleenor, R. E., Orfanakos, V. B., Casey, B. M., & Battarbee, A. N. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005609 · Cited by 23
Battarbee, A. N., Durnwald, C. P., Yee, L. M., & Valent, A. M. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005669 · Cited by 21
“8 Data to support the use of CGM to diagnose GDM in pregnancy are also limited but are actively being studied.”
Szmuilowicz, E. D., Barbour, L. A., Brown, F. M., Durnwald, C. P., Feig, D. S., O’Malley, G., Polsky, S., & Aleppo, G. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241239341 · Cited by 23
“6 Recommendations per current expert clinical guidance 3,4 for percentage of time spent within the pregnancy-specific TIR, TAR, and TBR are shown in Table 1 and are widely used in clinical practice.”
Self-citationGurza, G., Martínez-Cruz, N., Lizano-Jubert, I., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15091129 · Cited by 15
Disparities in Diabetes in Pregnancy and the Role of Social Determinants of Health
Dickens, L. T. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01587-1 · Cited by 17
“Glycemic monitoring in pregnancy is often recommended fasting, preprandial, and postprandial (6 times per day) and medical therapy with insulin can require injections up to 4–5 times per day [ 33].”
Zou, C., Shen, Q., Yang, Y., Liao, Y., & Du, Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1555409 · Cited by 18
Gazis, D., Tranidou, A., Siargkas, A., Apostolopoulou, A., Koutsouki, G., Goulis, D. G., Tsakalidis, C., Tsakiridis, I. G., & Dagklis, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134789 · Cited by 25
“The findings of our study are also in accord with reports by the International Diabetes Federation and the American Diabetes Association, both of which underscore the increased likelihood of poor pregnancy outcomes when PGDM is present [106,107].”
Life-course management of gestational diabetes mellitus: A narrative review
Luo, Q.-J., & Ni, Q. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i29.111096 · Cited by 16
The effect of obesity interventions on male fertility: a systematic review and meta-analysis
Peel, A., Lyons, H. E., Tully, C. A., Vincent, A. D., Jesudason, D. R., Wittert, G., & McPherson, N. O. (2025) · Human Reproduction Update · doi:10.1093/humupd/dmaf025 · Cited by 19
Beldie, L.-A., Dica, C.-C., Moța, M., Pirvu, B.-F., Burticală, M.-A., Mitrea, A., Clenciu, D., Efrem, I. C., Vladu, B. E., Timofticiuc, D. C. P., et al. (2024) · Nutrients · doi:10.3390/nu16234131 · Cited by 17
“A well-designed dietary plan for GDM typically includes a minimum of 71 g of protein, about 20–25% of daily intake, with a thoughtful balance between animal ad protein sources to maximize their nutritional benefits [103].”
Sambola, A., Campuzano, R., Castro, A., Goya, M., Coronado, P., Fernández-Olmo, R., Tablado, M. Á. M., Ortiz-Cortés, C., Ortolà, X., Pallarés‐Carratalá, V., et al. (2025) · Revista Española de Cardiología · doi:10.1016/j.recesp.2025.01.015 · Cited by 13
CASTORINO, K. N., Durnwald, C. P., Ehrenberg, S., Ehrhardt, N. M., Isaacs, D., Levy, C. J., Valent, A. M., & Continuous Glucose Monitoring for Gestational Diabetes Management Working Group (2024) · Journal of Women s Health · doi:10.1089/jwh.2023.0864 · Cited by 15
Athanasiadou, K. I., Paschou, S. Α., Markozannes, G., Vasileiou, V., Kanouta, F., Mitropoulou, M., Antsaklis, P. G., Theodora, M., Ψαλτοπούλου, Θ., Daskalakis, G. J., et al. (2025) · Endocrine · doi:10.1007/s12020-025-04329-1 · Cited by 13
“The high proportion of women requiring insulin therapy in our cohort, above the typical 15 – 30% range, re fl ects the higher prevalence of high-risk pregnancies managed at our referral tertiary hospital, where optimal care is provided for potential perinatal complications [18].”
Insulin Management for Gestational and Type 2 Diabetes in Pregnancy
Valent, A. M., & Barbour, L. A. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005640 · Cited by 16
Use of continuous glucose monitoring and hybrid closed‐loop therapy in pregnancy
Benhalima, K., & Yamamoto, J. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15999 · Cited by 15
Hughes, M. S., Pasquel, F. J., Davis, G. M., Lal, R., Buckingham, B. A., Boughton, C. K., Brown, S. A., & Bally, L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0343 · Cited by 14
“60,61 Allowing systems to reset their memory to establish a new base-line or reduce adaptivity constraints could enable more con fi dent AID use with minimal input during abrupt changes.”
Retnakaran, R. R., Ye, C., Kramer, C. K., Hanley, A. J., Connelly, P. W., Sermer, M., & Zinman, B. (2025) · Diabetes Care · doi:10.2337/dc24-1848 · Cited by 15
Du, R., Bai, Y., Li, L., Shao, Y., & Wu, N. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07419-0 · Cited by 17
“Physiological IR during pregnancy supports fetal energy supply, but excessive IR can overwhelm maternal insulin production, leading to GDM [3].”
Heterogeneity of Gestational Diabetes and Risk for Adverse Pregnancy Outcome: A Cohort Study
Gong, Y., Wang, Q., Chen, S., Liu, Y., Li, C., Kang, R., Wang, J., Wei, T., Wang, Q., Li, X., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae754 · Cited by 13
Won, S., Kim, H. J., Park, J. Y., Oh, K. J., Choi, S. H., Jang, H. C., & Moon, J. H. (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e46 · Cited by 12
“32-34 One meta-analysis of the efficacy of CGM in GDM, including six studies, reported that women with GDM using CGM may achieve lower average blood”
Nunes, M. L., Félix, B., Nunes, F., & Santos, I. (2025) · Scientific Reports · doi:10.1038/s41598-025-96318-7 · Cited by 12
li, J., Liu, X., He, S., & Ren, Y. (2025) · JMIR Medical Informatics · doi:10.2196/71539 · Cited by 14
“Current clinical guidelines recommend screening for gestational diabetes between 24 and 28 weeks of pregnancy, and screening for and treating gestational diabetes during this period can significantly reduce the risk of adverse pregnancy outcomes [4,22].”
Decoding the Gut Microbiota–Gestational Diabetes Link: Insights from the Last Seven Years
Balleza-Alejandri, L. R., Peña-Durán, E., Beltrán-Ramírez, A., Reynoso-Roa, A. S., Sánchez-Abundis, L. D., García-Galindo, J. J., & Suárez-Rico, D. O. (2024) · Microorganisms · doi:10.3390/microorganisms12061070 · Cited by 12
Case series of a hybrid closed loop therapy system used in pregnancy
Brigham, T. L., Klein, M. P., Snell‐Bergeon, J. K., & Polsky, S. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02469-4 · Cited by 9
“We discussed the importance of inputting all carbohydrate loads and adhering to recommended carbohydrate goals of pregnancy (175 g/day in divided doses [3]), as HCL systems may not adequately control glucose levels in the setting of excessive carbohydrate consumption.”
InfluentialSelf-citationYan, M., Chen, Z., Tang, J., Duan, X., Peng, W., Liu, R., Li, W., Hu, Z., & Liu, Y. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07423-4 · Cited by 8
“…increased likelihood of experiencing adverse perinatal outcomes, including encompassing shoulder dystocia, neonatal hypoglycemia, stillbirth, growth abnormalities (both large and small for gestational age), preterm birth, low Apgar scores, and admission to the neonatal intensive care unit [4, 6–9].”
García‐Patterson, A., Balsells, M., Solà, I., & Corcoy, R. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.04.059 · Cited by 18
Continuous glucose monitoring system in diabetes in pregnancy: a narrative review
Rodacki, M., Krakauer, M., Franco, D. R., Dualib, P. M., Sancovski, M., & Zajdenverg, L. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01854-x · Cited by 15
“…in Diabetes Care recently added a recommendation that CGM metrics may be used in combination with blood glucose monitoring to achieve optimal pre-and postprandial glycemic goals in pregnancy [3], prior the 2024 standards that CGM metrics did not recommend it as a substitute for BGM metrics [70].”
Ehrhardt, N. M., Fonda, S. J., Mandava, P., ABDALLA, G., & Fay, E. (2025) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2025.101878 · Cited by 10
Perea, V., Quirós, C., Herrera-Arranz, M. T., Azriel, S., Wägner, A. M., Beato-Víbora, P. I., Soldevila, B., Barquiel, B., Pardo, R. M., Díaz-Soto, G., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02430-x · Cited by 9
Contraception and nonalcoholic fatty liver disease in women with prior gestational diabetes mellitus
Sethasine, S., Suthasmalee, S., Tangjitgamol, S., et al. (2025) · Contraception · doi:10.1016/j.contraception.2025.110860 · Cited by 8
Management of Diabetes in Pregnancy: A Review of Clinical Guidelines and Practices
Albairmani, R. A., Basheer, B., Macky, M. M., Syouti, T. A., AlZubaidy, H., Elfaki, E., Kidwai, A., Basheer, Y. M., Ahmed, F., & Salaheldin, M. (2025) · Cureus · doi:10.7759/cureus.79334 · Cited by 28
“Their guidelines also stress the need for a multidisciplinary team to manage diabetes in pregnant women, which may include obstetricians, endocrinologists, dietitians, and diabetes educators [9].”
InfluentialLack of Validity of the Glucose Management Indicator in Type 1 Diabetes in Pregnancy
Meek, C. L., Feig, D. S., SCOTT, E. M., Corcoy, R., Murphy, H. R., & CONCEPTT Collaborative Group (2025) · Diabetes Care · doi:10.2337/dc24-2494 · Cited by 8
Huhn, E. A., Kotzaeridi, G., Fischer, T., Bernasconi, M. T., Richter, A. S., Kunze, M., Dölzlmüller, E., Jaksch‐Bogensperger, H., Weidinger, L., Eppel, D., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06517-0 · Cited by 10
“In line with local and international guidelines, insulin was indicated if either fasting or 1 h postprandial glucose exceeded 5.3 mmol/l (95 mg/dl) or 7.8 mmol/l (140 mg/dl), respectively, for more than two measures in a period of 1 week [22, 23].”
InfluentialDudzik, D., Atanasova, V. B., Barbas, C., & Bartha, J. L. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1452312 · Cited by 11
Carlson, A. L., Beck, R. W., Li, Z., Norton, E., Bergenstal, R. M., Johnson, M. L., DUNNIGAN, S. M., Banfield, M., KRUMWIEDE, K. J., Sibayan, J., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0563 · Cited by 9
Demidowich, A. P., Stanback, C., & Zilbermint, M. F. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15190 · Cited by 13
Bovee, L. B., & Hirsch, I. B. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0028 · Cited by 10
Xu, J., Zhang, F., Li, H., et al. (2024) · Journal of Diabetes Research · doi:10.1155/2024/1518080 · Cited by 6
“However, the side e ff ects of presenting some risks for foetal growth and development are still major obstacles in GDM treatment [13, 15 – 17].”
Approach to the Patient Using Diabetes Technology in Pregnancy
Dickens, L. T., & González, M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae914 · Cited by 6
Storey, K. M., Shay, L. A., Poteat, T., Pennington, K. A., & Schulz, L. C. (2025) · Reproduction · doi:10.1530/rep-25-0050 · Cited by 8
Dunne, P., Culliney, L., O’Mahony, L., Byrne, M., Murphy, A. W., & O'Reilly, S. L. (2024) · Diabetic Medicine · doi:10.1111/dme.15373 · Cited by 7
“14 The available and current guidelines for GDM management 9,14–16 do however have many aspects where they lack consensus.”
Diabetes Technology Use in Special Populations: A Narrative Review of Psychosocial Factors
Hughes, M. S., Aleppo, G., Bally, L., Batista, A. F. M. B., Brown, S. A., Faulds, E. R., Gonder-Frederick, L. A., Isaacs, D. M., Kahkoska, A. R., Ortega, J., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241296853 · Cited by 6
“50,51 Despite the generally high motivation in this population, studies suggest only 50% of people in pregnancy reach the recommended glucose targets.”
Self-citationDiabetes Mellitus in Pregnancy: Implications for Obstetric Anesthesia
Rogers, W. K., Chugaieva, I., Moheet, A. A., & Wernimont, S. A. (2025) · Obstetric Anesthesia Digest · doi:10.1097/01.aoa.0001192196.21020.41 · Cited by 7
Dang, N.-A. T., Ái, N. T., Dung, V. T. K., Nguyen, T. M. P., Tiến, N. V., Gammeltoft, T. M., Bygbjerg, I. C., & Vestergaard, A. R. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-08399-x · Cited by 5
“Most recommendations suggest that T2D screening should be conducted within the 12th week postpartum with an oral glucose tolerance test (OGTT) [4, 7].”
Diabetes prevention after gestational diabetes: challenges and opportunities
Dunne, P., Sherry, D., & O'Reilly, S. L. (2024) · Proceedings of The Nutrition Society · doi:10.1017/s0029665124007456 · Cited by 9
“These further tests can be performed using any suitable glycaemic test, such as glycated haemoglobin (HbA1c), fasting plasma glucose or OGTT, using non-pregnant thresholds (12) .”
InfluentialAssociation Between Glycemia, Glycemic Variability, and Pregnancy Complications in Early GDM
Immanuel, J., Cheung, N. W., Mohajeri, M., Simmons, D. S., Hague, W. M., Teede, H. J., Nolan, C. J., Peek, M. J., Flack, J. R., McLean, M. P., et al. (2024) · Diabetes Care · doi:10.2337/dc24-1199 · Cited by 5
DiStefano, M. J., McQueen, R. B., Gao, V., Klein, M. P., Snell‐Bergeon, J. K., & Polsky, S. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0478 · Cited by 6
“As such, guidelines recommended that pregnant CGM users still perform multiple SMBG tests daily, 1 which is why we assumed a rate of three SMBGs performed daily in this group for the real-world scenario.”
Self-citationTahir, S., Naeem, S., Nayyab, I., Batool, A., Emeish, S., Hasan, I., Dhir, A., Shahid, J., Sheraz, M. A., Singh, J., et al. (2025) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2025.113969 · Cited by 5
Sirico, A., Vastarella, M. G., Ruggiero, E., & Cobellis, L. (2025) · Nutrients · doi:10.3390/nu17142356 · Cited by 8
“ADA [12], Diabetes Canada [13], and KDA [11] recommend targeting either 140 mg/dL (7.8 mmol/L) at 1-h or 120 mg/dL (6.7 mmol/L) at 2-h post-meal.”
Influentialda‐Costa‐Santos, J., Reis, V. V. L., Japecanga, R. R., Seabra, M., Carvalho, M. A., Oliveira, A. J. G., Vinchi, L. C., Righi, A. B. P., Mayrink, J., Guida, J. P. D. S., et al. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70434 · Cited by 4
Philis‐Tsimikas, A., Aberle, J., BAJAJ, H. S., Lingvay, I., Mu, Y., Shaikh, S. S., Vianna, A. G. D., Watada, H., & Prato, S. D. (2025) · Drugs · doi:10.1007/s40265-025-02201-0 · Cited by 10
“Treatment guidelines stipulate that insulin should be administered alongside medical nutrition therapy to control pre-existing T2D among pregnant individuals [36].”
Self-citationLee, S. U., Hong, S., Choi, S. K., Kim, S. M., Shin, J. E., Kil, K., Kim, Y. H., Wie, J. H., Jo, Y. S., & Ko, H. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-57535-8 · Cited by 5
Milionis, C., Ilias, Ι., & Koukkou, E. G. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.860 · Cited by 7
Gupta, Y., Goyal, A., & Tandon, N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15722 · Cited by 4
Dunne, P., O’Mahony, L., Culliney, L., Byrne, M., Murphy, A. W., & O'Reilly, S. L. (2024) · Diabetic Medicine · doi:10.1111/dme.15489 · Cited by 6
“1,26 This underscores the importance of addressing the emotional aspects of GDM management, both antenatally and postpartum.”
Sambola, A., Campuzano, R., Castro, A., Goya, M., Coronado, P., Fernández-Olmo, R., Tablado, M. Á. M., Ortiz-Cortés, C., Ortolà, X., Pallarés‐Carratalá, V., et al. (2025) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2025.01.005 · Cited by 10
“36 Currently, there are no specific recommendations for patients with spontaneous gestational losses or spontaneous preterm births, as there are for women with pre-eclampsia.”
Association of Circulating GDF-15 with Fetal Growth in Gestational Diabetes
Filardi, T., Bleve, E., Viggiani, V., Galoppi, P., Rizzo, G., Gorini, S., Caprio, M., Angeloni, A., Morano, S., & Anastasi, E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082764 · Cited by 4
“Gestational diabetes mellitus (GDM) refers to glucose intolerance that typically manifests during the second or third trimester of gestation [4].”
Montemayor, M. T., Lesniara-Stachon, A., Heinzer, R. C., Collet, T., Dizès, O. L., Horsch, A., Quansah, D. Y., & Puder, J. J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119510 · Cited by 6
“Gestational Diabetes Mellitus (GDM) is defined as glucose intolerance first diagnosed during pregnancy that does not fulfil the criteria of overt diabetes (American Diabetes Association Professional Practice Committee, 2024).”
Shen, Y., & Hu, G. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22919 · Cited by 6
King, J., Buschur, E., Snell-Bergeon, J., Pyle, L., Dungan, K., Garcetti, R., Nease, E., Bartholomew, A., Johnson, C., & Polsky, S. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241260050 · Cited by 3
Self-citationZheng, R., Du, L., Zhu, X., Zhang, X., Han, W., & Yang, Z. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07375-9 · Cited by 3
“…6 days) or postterm (≥ 42 weeks) pregnancy, diabetes in pregnancy (including type 1 diabetes, type 2 diabetes and gestational diabetes mellitus) [16], hypertensive disorders of pregnancy (HDP), fetal and amniotic fluid disorders (e.g., fetal growth restriction, reduced fetal movement, suspected…”
Deng, Y., Wan, S., Yuan, Z., & Yang, H. (2025) · Advanced Science · doi:10.1002/advs.202411126 · Cited by 3
Fetal Pancreatic Circumference as a Predictor of Gestational Diabetes Mellitus During 75 g OGTT
Keven, M. C., Aydoğdu, E., Yeğen, B. D., Yucel, E., Bütün, Z., & Tanaçan, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155414 · Cited by 3
“However, with early diagnosis, dietary modifications, exercise, and pharmacological treatment (when necessary), normal blood glucose levels can be achieved, significantly reducing maternal, fetal, and neonatal complications [3,4,18,21].”
Kishimoto, M., Tamaru, S., & Odawara, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-23404-1 · Cited by 7
Elkind-Hirsch, K. E., ARMATTA, M. L., Hames, K. C., & VEILLON, E. W., Jr. (2025) · Expert Review of Medical Devices · doi:10.1080/17434440.2025.2607631 · Cited by 3
Silva, K., Valero, P., Espinoza, F., Rivas, J. C., Sauceda-Acosta, D., & Sobrevía, L. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_803 · Cited by 5
Jung, A. R., Seo, Y., Lee, J., Hwang, J. G., Yun, S., & Lee, D. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175004 · Cited by 4
“The 2024 guidelines from the ADA recommend that patients with GDM engage in physical activity at least twice a week for a minimum of 20 to 50 min, focusing on moderate-intensity aerobic exercises, resistance training, or a combination of both [45].”
MethodMirabelli, M., Tocci, V., CHIEFARI, E. D., Iuliano, S., Brunetti, F. S., Misiti, R., Giuliano, S., Greco, M., FOTI, D. P., & Brunetti, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175200 · Cited by 4
“Current recommendations for managing GDM aim to replicate the physiological gestational glucose profile as closely as possible, maintaining fasting blood glucose levels below 90 mg/dL and 1-h postprandial levels below 130 mg/dL, with minimal variations across guidelines [15,30,31].”
BackgroundCitro, F., Bianchi, C., Belcari, T., Galleano, F., Venturi, C., Battini, L., Marchetti, P., Bertolotto, A., & Aragona, M. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241289957 · Cited by 5
Kim, M. J., Park, S., Choi, S., Hong, S., Sung, J., Seol, H., Lee, J. H., Kim, S. C., Choi, S.-K., Kwon, J. Y., et al. (2024) · Life · doi:10.3390/life14121575 · Cited by 3
Phonyiam, R., Teng, C., Cortés, Y. I., et al. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004205 · Cited by 3
Garvey, Z., Gupta, A., Taylor, N., Thirunavukkarasu, M., & Maulik, N. (2025) · Metabolites · doi:10.3390/metabo15030180 · Cited by 4
“Lifestyle intervention is multifaceted with differing approaches to each aspect, yet the most effective of these approaches account for four key factors [35].”
Pregnancy-related Thrombotic Microangiopathy has a spectrum of underlying causes
Livson, S., Heikkinen‐Eloranta, J., Messing, M., Lokki, A. I., & Meri, S. (2025) · Pregnancy Hypertension · doi:10.1016/j.preghy.2025.101212 · Cited by 3
Lachaud, A. E., & Durnwald, C. P. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0148 · Cited by 3
Guo, Z., Ji, W., Yan, M., Zou, X., Chen, T., Bai, F., Wu, Y., Guo, Z., & Song, L. (2025) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2025.1528661 · Cited by 3
Cichocka, E., & Gumprecht, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195797 · Cited by 4
“Predisposition to GDM is present before pregnancy, and hormonal changes and weight gain during pregnancy finally lead to the manifestation of GDM [1,2].”
BackgroundInfluentialA strategic framework for managing gestational diabetes in Mexico
Martínez‐Juárez, L. A., Gallardo‐Rincón, H., Saucedo-Martínez, R., Mújica‐Rosales, R., Reyes-Muñoz, E., Álvarez-Hernández, D.-A., & Tapia‐Conyer, R. (2025) · Global Health Research and Policy · doi:10.1186/s41256-025-00406-0 · Cited by 3
“…health policy should strengthen the screening, diagnosis, and management of GDM. • First, the adherence to globally recognized screening algorithms, such as the one proposed by the American Diabetes Association (ADA) and national guidelines [11], should be ensured across all health care facilities.”
Huang, J., Forde, R., Forbes, A., & Parsons, J. (2025) · Diabetic Medicine · doi:10.1111/dme.70043 · Cited by 2
Diabetes Technology Use in Pregnancies with Type 1 Diabetes in the United States from 2009 to 2020
Sobhani, N. C., Huang, Y., Venkatesh, K. K., Wright, J. D., Friedman, A. M., & Wen, T. (2025) · American Journal of Perinatology · doi:10.1055/a-2625-6437 · Cited by 2
“32 Despite these fi ndings and recommendations, the overall rate of CGM use in pregnancy remained low in our study, at just 13.7% in 2020.”
InfluentialDrummond, R. F., Seif, K. E., Higgs, A. J., & Reece, E. A. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.08.088 · Cited by 3
Lyu, L., Huang, Y., Huang, Y., Wu, Z., Ping, F., & Li, Y. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i8.106967 · Cited by 2
Ziyanok, S. (2025) · Doğu Karadeniz Sağlık Bilimleri Dergisi · doi:10.59312/ebshealth.1765591 · Cited by 2
Palatnik, A., & Feghali, M. N. (2024) · American Journal of Perinatology · doi:10.1055/a-2407-0905 · Cited by 3
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S282-S294
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725801
- OpenAlex
- W4389560993
- Semantic Scholar
- 1f3e4a9c0ae2be86d5da282aa96908a6bda368a2
- Cited by
- 232
- References
- 147
- Citations by year
- 2026: 60 · 2025: 106 · 2024: 66
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- diabetes in pregnancy, gestational diabetes mellitus, clinical guidelines, treatment goals, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Female, Humans, Pregnancy, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.